Market Research Logo

Antibodies Market: Global Industry Analysis and Opportunity Assessment 2016 - 2026

Antibodies Market: Global Industry Analysis and Opportunity Assessment 2016 - 2026

Future market insights offers a 10-year forecast on the global market for antibodies between 2016 and 2026. The global antibodies market is expected to witness a robust CAGR of 12.5% over the forecast period. The study demonstrates market dynamics that are expected to influence the current environment and future status of the global antibodies market over the forecast period. The primary objective of this report is to offer updates on trends, drivers, restraints, value forecasts, and opportunities for manufacturers operating in the global antibodies market.

Global demand for antibodies is increasing with growing burden of chronic illnesses such as cancer, autoimmune disorders and others. Developed markets such as the U.S. and Europe are witnessing increasing demand for antibody-based drugs due to rising demand for better treatment options. To understand and analyse the market, the report is categorically split into four sections, viz. market analysis by drug type, end user, indication, and regions. The report analyses the global antibodies market in terms of value (US$ Mn).

The global antibodies market is segmented on the basis of

Drug type
End User
Disease Indication
Region

The report begins with the market definition and defining different product types. This is followed by the overview on evolution of antibody based drugs. The market dynamics section includes FMI’s analysis on key trends, drivers, restraints, opportunities and macro factors influencing global antibodies market. Impact analysis of key growth drivers and restraints based on weighted average model has also been included in the report to better equip clients with crystal clear decision making insights.

The next section of the report analyses the market based on drug type and presents the forecast in terms of value for the next 10 years. Drug types covered in the report include:

Monoclonal antibodies
Polyclonal antibodies
Antibody drug conjugates

Monoclonal antibodies drug type segment holds highest market share in global antibodies market owing to high potential of these drugs for use in targeted therapies. Antibody-drug conjugates drug-type segment is expected to grow at significant CAGR over the forecast period due to unique property of exerting combined therapeutic effect of antibody and conjugated drug.

The next section of the report analyses market based on end user and presents the forecast in terms of value for the next ten years. The end users covered in this report are:

Hospitals
Long-term care facilities
Research institutes

The next section of the report analyses the market based on indications and presents the forecast in terms of value for the next ten years. The indications covered in the report include:

CNS Disorders
Cardiovascular Diseases
Cancer
Autoimmune disorders

Furthermore, the report analyses the market based on regions and presents the forecast in terms of value for the next ten years. Regions covered in the report include:

North America
U.S.
Canada
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Western Europe
UK
Germany
France
Spain
Italy
Nordic
Benelux
Rest of Western Europe
Eastern Europe
Russia
Poland
Rest of Eastern Europe
Asia Pacific Excluding Japan
China
India
ASEAN
Australia & New Zealand
Rest of APEJ
Middle East & Africa (MEA
GCC Countries
South Africa
North Africa
Rest of MEA
Japan

In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global antibodies market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the antibodies market. To understand key growth segments, Future Market Insights provides the ‘Attractiveness Index’ analysis. The resulting index helps providers to identify real market opportunities.

In the final section of the report on antibodies market, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, to access the key differentiators among the competitor firms. Key categories of providers covered in the report are drug types. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the urinary tract infection value chain and the potential players with regard to the same. However, this section also includes market strategies and SWOT analysis of the main players in the market.

Detailed profiles of the medical device companies are also included in the scope of the report to evaluate their long-term and short-term strategies. Key players in the market include Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co.


1. Executive Summary
2. Assumptions and Acronyms
3. Research Methodology
4. Antibodies Market Overview
4.1. Introduction
4.1.1. Antibodies Market Definition
4.1.2. Antibodies Market Taxonomy
4.1.3. Antibodies Market Product Type Overview
4.1.4. Overview
4.2. Antibodies Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Regulations
5. Global Antibodies Market Forecast
5.1. Market Value (US$ Mn) Forecast
5.1.1. Y-o-Y Growth Projections
5.1.2. Absolute $ Opportunity
5.2. Antibodies Market Trends
5.2.1. Market Share, By Region
5.2.2. Market Share, By Product Type
5.2.3. Market Share, By End User
5.2.4. Market Share, By Disease Indication
6. Global Antibodies Market Analysis, By Product Type
6.1. Introduction
6.1.1. Y-o-Y Growth Comparison, By Product Type
6.1.2. Market Share & Basis Point (BPS) Analysis, By Product Type
6.2. Market Forecast, By Product Type
6.2.1. Monoclonal antibodies
6.2.1.1. Absolute $ Opportunity
6.2.1.2. Market Value (US$ Mn) Forecast
6.2.2. Polyclonal antibodies
6.2.2.1. Absolute $ Opportunity
6.2.2.2. Market Value (US$ Mn) Forecast
6.2.3. Antibody-drug complexes (ADCs)
6.2.3.1. Absolute $ Opportunity
6.2.3.2. Market Value (US$ Mn) Forecast
6.3. Market Attractiveness Analysis, By Product Type
6.4. Prominent Trends
7. Global Antibodies Market Analysis, By Disease Indication
7.1. Introduction
7.1.1. Y-o-Y Growth Comparison, By Disease Indication
7.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication
7.2. Market Forecast, By Disease Indication
7.2.1. Cardiovascular diseases
7.2.1.1. Absolute $ Opportunity
7.2.1.2. Market Value (US$ Mn) Forecast
7.2.2. CNS disorders
7.2.2.1. Absolute $ Opportunity
7.2.2.2. Market Value (US$ Mn) Forecast
7.2.3. Cancer
7.2.3.1. Absolute $ Opportunity
7.2.3.2. Market Value (US$ Mn) Forecast
7.2.4. Autoimmune Disorders
7.2.4.1. Absolute $ Opportunity
7.2.4.2. Market Value (US$ Mn) Forecast
7.3. Market Attractiveness Analysis, By Disease Indication
7.4. Prominent Trends
8. Global Antibodies Market Analysis, By End User
8.1. Introduction
8.1.1. Y-o-Y Growth Comparison, By End User
8.1.2. Market Share & Basis Point (BPS) Analysis, By End User
8.2. Market Forecast, By End User
8.2.1. Hospitals
8.2.1.1. Absolute $ Opportunity
8.2.1.2. Market Value (US$ Mn) Forecast
8.2.2. Long-term Care Facilities
8.2.2.1. Absolute $ Opportunity
8.2.2.2. Market Value (US$ Mn) Forecast
8.2.3. Research institutes
8.2.3.1. Absolute $ Opportunity
8.2.3.2. Market Value (US$ Mn) Forecast
8.3. Market Attractiveness Analysis, By End User
8.4. Prominent Trends
9. Global Antibodies Market Analysis, By Region
9.1. Introduction
9.1.1. Y-o-Y Growth Projections, By Region
9.1.2. Market Share & Basis Point (BPS) Analysis, By Region
9.2. Market Forecast, By Region
9.2.1. North America Market Value (US$ Mn) Forecast
9.2.2. Latin America Market Value (US$ Mn) Forecast
9.2.3. Western Europe Market Value (US$ Mn) Forecast
9.2.4. Eastern Europe Market Value (US$ Mn) Forecast
9.2.5. Asia Pacific Excl. Japan Market Value (US$ Mn) Forecast
9.2.6. Japan Market Value (US$ Mn) Forecast
9.2.7. MEA Market Value (US$ Mn) Forecast
9.3. Regional Attractiveness Analysis
10. North America Antibodies Market Analysis
10.1. Introduction
10.1.1. Y-o-Y Growth Projections, By Country
10.1.2. Market Share & Basis Point (BPS) Analysis, By Country
10.2. Key Regulations
10.3. Key Trends
10.4. North America Market Forecast
10.4.1. Market Value (US$ Mn) Forecast, By Country
10.4.1.1. U.S. Absolute $ Opportunity
10.4.1.2. Canada Absolute $ Opportunity
10.4.2. Market Value (US$ Mn) Forecast, By Product Type
10.4.2.1. Monoclonal antibodies
10.4.2.2. Polyclonal antibodies
10.4.2.3. Antibody-drug complexes (ADCs)
10.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
10.4.3.1. Cardiovascular diseases
10.4.3.2. CNS disorders
10.4.3.3. Cancer
10.4.3.4. Autoimmune Disorders
10.4.4. Market Value (US$ Mn) Forecast, By End User
10.4.4.1. Hospitals
10.4.4.2. Long-term Care Facilities
10.4.4.3. Research institutes
10.5. Market Attractiveness Analysis
10.5.1. By Country
10.5.2. By Product Type
10.5.3. By End User
10.5.4. By Disease Indication
10.6. Drivers & Restraints: Impact Analysis
11. Latin America Antibodies Market Analysis
11.1. Introduction
11.1.1. Y-o-Y Growth Projections, By Country
11.1.2. Market Share & Basis Point (BPS) Analysis, By Country
11.2. Key Regulations
11.3. Key Trends
11.4. Latin America Market Forecast
11.4.1. Market Value (US$ Mn) Forecast, By Country
11.4.1.1. Argentina Absolute $ Opportunity
11.4.1.2. Brazil Absolute $ Opportunity
11.4.1.3. Mexico Absolute $ Opportunity
11.4.1.4. Rest of Latin America Absolute $ Opportunity
11.4.2. Market Value (US$ Mn) Forecast, By Product Type
11.4.2.1. Monoclonal antibodies
11.4.2.2. Polyclonal antibodies
11.4.2.3. Antibody-drug complexes (ADCs)
11.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
11.4.3.1. Cardiovascular diseases
11.4.3.2. CNS disorders
11.4.3.3. Cancer
11.4.3.4. Autoimmune Disorders
11.4.4. Market Value (US$ Mn) Forecast, By End User
11.4.4.1. Hospitals
11.4.4.2. Long-term Care Facilities
11.4.4.3. Research institutes
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Product Type
11.5.3. By End User
11.5.4. By Disease Indication
11.6. Drivers & Restraints: Impact Analysis
12. Western Europe Antibodies Market Analysis
12.1. Introduction
12.1.1. Y-o-Y Growth Projections, By Country
12.1.2. Market Share & Basis Point (BPS) Analysis, By Country
12.2. Key Regulations
12.3. Key Trends
12.4. Western Europe Market Forecast
12.4.1. Market Value (US$ Mn) Forecast, By Country
12.4.1.1. U.K. Absolute $ Opportunity
12.4.1.2. Germany Absolute $ Opportunity
12.4.1.3. France Absolute $ Opportunity
12.4.1.4. Spain Absolute $ Opportunity
12.4.1.5. Italy Absolute $ Opportunity
12.4.1.6. Nordic Countries Absolute $ Opportunity
12.4.1.7. Rest of Western Europe Absolute $ Opportunity
12.4.2. Market Value (US$ Mn) Forecast, By Product Type
12.4.2.1. Monoclonal antibodies
12.4.2.2. Polyclonal antibodies
12.4.2.3. Antibody-drug complexes (ADCs)
12.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
12.4.3.1. Cardiovascular diseases
12.4.3.2. CNS disorders
12.4.3.3. Cancer
12.4.3.4. Autoimmune Disorders
12.4.4. Market Value (US$ Mn) Forecast, By End User
12.4.4.1. Hospitals
12.4.4.2. Long-term Care Facilities
12.4.4.3. Research institutes
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Product Type
12.5.3. By End User
12.5.4. By Disease Indication
12.6. Drivers & Restraints: Impact Analysis
13. Eastern Europe Antibodies Market Analysis
13.1. Introduction
13.1.1. Y-o-Y Growth Projections, By Country
13.1.2. Market Share & Basis Point (BPS) Analysis, By Country
13.2. Key Regulations
13.3. Key Trends
13.4. Eastern Europe Market Forecast
13.4.1. Market Value (US$ Mn) Forecast, By Country
12.4.1.1. Poland Absolute $ Opportunity
12.4.1.2. Russia Absolute $ Opportunity
12.4.1.3. Rest of Eastern Europe Absolute $ Opportunity
13.4.2. Market Value (US$ Mn) Forecast, By Product Type
13.4.2.1. Monoclonal antibodies
13.4.2.2. Polyclonal antibodies
13.4.2.3. Antibody-drug complexes (ADCs)
13.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
13.4.3.1. Cardiovascular diseases
13.4.3.2. CNS disorders
13.4.3.3. Cancer
13.4.3.4. Autoimmune Disorders
13.4.4. Market Value (US$ Mn) Forecast, By End User
13.4.4.1. Hospitals
13.4.4.2. Long-term Care Facilities
13.4.4.3. Research institutes
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Product Type
13.5.3. By End User
13.5.4. By Disease Indication
13.6. Drivers & Restraints: Impact Analysis
14. Asia Pacific Excl. Japan Antibodies Market Analysis
14.1. Introduction
14.1.1. Y-o-Y Growth Projections, By Country
14.1.2. Market Share & Basis Point (BPS) Analysis, By Country
14.2. Key Regulations
14.3. Key Trends
14.4. Asia Pacific Excl. Japan Market Forecast
14.4.1. Market Value (US$ Mn) Forecast, By Country
14.4.1.1. China Absolute $ Opportunity
14.4.1.2. India Absolute $ Opportunity
14.4.1.3. ASEAN Absolute $ Opportunity
14.4.1.4. Australia & New Zealand Absolute $ Opportunity
14.4.1.5. Rest of APEJ Absolute $ Opportunity
14.4.2. Market Value (US$ Mn) Forecast, By Product Type
14.4.2.1. Monoclonal antibodies
14.4.2.2. Polyclonal antibodies
14.4.2.3. Antibody-drug complexes (ADCs)
14.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
14.4.3.1. Cardiovascular diseases
14.4.3.2. CNS disorders
14.4.3.3. Cancer
14.4.3.4. Autoimmune Disorders
14.4.4. Market Value (US$ Mn) Forecast, By End User
14.4.4.1. Hospitals
14.4.4.2. Long-term Care Facilities
14.4.4.3. Research institutes
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Product Type
14.5.3. By End User
14.5.4. By Disease Indication
14.6. Drivers & Restraints: Impact Analysis
15. Japan Antibodies Market Analysis
15.1. Introduction
15.2. Key Regulations
15.3. Key Trends
15.4. Japan Market Forecast
15.4.1. Market Value (US$ Mn) Forecast, By Product Type
15.4.1.1. Monoclonal antibodies
15.4.1.2. Polyclonal antibodies
15.4.1.3. Antibody-drug complexes (ADCs)
15.4.2. Market Value (US$ Mn) Forecast, By Disease Indication
15.4.2.1. Cardiovascular diseases
15.4.2.2. CNS disorders
15.4.2.3. Cancer
15.4.2.4. Autoimmune Disorders
15.4.3. Market Value (US$ Mn) Forecast, By End User
15.4.3.1. Hospitals
15.4.3.2. Long-term Care Facilities
15.4.3.3. Research institutes
15.5. Market Attractiveness Analysis
15.5.1. By Product Type
15.5.2. By End User
15.5.3. By Disease Indication
15.6. Drivers & Restraints: Impact Analysis
16. MEA Antibodies Market Analysis
16.1. Introduction
16.1.1. Y-o-Y Growth Projections, By Country
16.1.2. Market Share & Basis Point (BPS) Analysis, By Country
16.2. Key Regulations
16.3. Key Trends
16.4. MEA Market Forecast
16.4.1. Market Value (US$ Mn) Forecast, By Country
16.4.1.1. GCC Countries Absolute $ Opportunity
16.4.1.2. South Africa Absolute $ Opportunity
16.4.1.3. North Africa Absolute $ Opportunity
16.4.1.4. Rest of MEA Absolute $ Opportunity
16.4.2. Market Value (US$ Mn) Forecast, By Product Type
16.4.2.1. Monoclonal antibodies
16.4.2.2. Polyclonal antibodies
16.4.2.3. Antibody-drug complexes (ADCs)
16.4.3. Market Value (US$ Mn) Forecast, By Disease Indication
16.4.3.1. Cardiovascular diseases
16.4.3.2. CNS disorders
16.4.3.3. Cancer
16.4.3.4. Autoimmune Disorders
16.4.4. Market Value (US$ Mn) Forecast, By End User
16.4.4.1. Hospitals
16.4.4.2. Long-term Care Facilities
16.4.4.3. Research institutes
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Product Type
16.5.3. By End User
16.5.4. By Disease Indication
16.6. Drivers & Restraints: Impact Analysis
17. Competition Landscape
17.1. Company Share Analysis
17.2. Competition Dashboard
17.3. Company Profiles Inclusions
17.3.1. Revenue
17.3.2. Products/Brand Offerings
17.3.3. Key developments
17.3.4. SWOT Analysis
17.4. Company Profiled
17.4.1. Novartis AG
17.4.2. F. Hoffmann-La Roche Ltd.
17.4.3. Johnson & Johnson Services, Inc.
17.4.4. Takeda Pharmaceutical Company Limited
17.4.5. Amgen Inc.
17.4.6. Biogen Inc.
17.4.7. Bristol-Myers Squibb Company
17.4.8. AbbVie Inc.
17.4.9. Sanofi
17.4.10. Eli Lilly and Co.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report